Why the study?
Cardiac involvement is a major determinant of poor prognosis in idiopathic inflammatory myopathies, but the role of sST2 has scarcely been explored.
Does the biomarker sST2 associate with cardiac involvement and decline after treatment in patients with idiopathic inflammatory myopathies?
Does the biomarker sST2 associate with cardiac involvement and decline after treatment in patients with idiopathic inflammatory myopathies?
sST2 is a promising biomarker for the early detection and monitoring of cardiac inflammation and involvement in patients with idiopathic inflammatory myopathies.
sST2 elevation may flag CI risk in new IIM but should not yet alter practice; leaves open prospective validation as a biomarker.
OBJECTIVE: Cardiac involvement (CI) is a major determinant of poor prognosis in idiopathic inflammatory myopathies (IIM). Soluble suppression of tumorigenicity 2 (sST2) is a biomarker linked to cardiac inflammation and remodelling, but its role has scarcely been explored in IIM. We aimed to investigate the levels of sST2 and its longitudinal profile in patients with IIM and CI. METHODS: Serum sST2 levels were measured longitudinally over the course of two years in 34 patients with newly diagnosed IIM and in 109 patients with established IIM from a cross-sectional cohort, as well as in age and gender matched healthy controls (HC) and in patients with rheumatoid arthritis (RA). CI was assessed using cardiac magnetic resonance (CMR) in newly diagnosed IIM patients. Associations between sST2 and clinical parameters were analyzed. RESULTS: Patients with newly diagnosed IIM exhibited significantly higher sST2 levels at diagnosis compared to HC (P < 0.0001) and patients with established IIM (P < 0.0001). sST2 levels were highest at diagnosis, decreased significantly by 6 months, and remained lower during follow-up. sST2 levels were positively associated with cardiac troponin I and N-terminal pro-brain natriuretic peptide (P = 0.0001 and P = 0.0001, respectively). Importantly, IIM patients with active CMR-verified CI exhibited significantly higher sST2 levels than those without ongoing CI. In contrast, patients with established IIM had sST2 levels comparable to HC and RA patients. CONCLUSION: sST2 is elevated in early IIM and closely associated with cardiac biomarkers and CMR-verified cardiac inflammation. Its dynamic decline with treatment suggests potential utility as a biomarker for early detection and monitoring of CI in IIM.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: